5,6-dimethyl-2-oximino-1-indanone | 112631-52-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 5,6-dimethyl-2-oximino-1-indanone
• 英文别名: 2-hydroxyimino-5,6-dimethylindan-1-one；5,6-dimethylindan-1,2-dione 2-oxime；2-hydroxyimino-5,6-dimethyl-3H-inden-1-one
• CAS: 112631-52-4
• 化学式: C₁₁H₁₁NO₂
• 分子量: 189.214
• InChiKey: BEQZRAJXMRJENN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  49.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5,6-dimethyl-2-oximino-1-indanone 在 盐酸 、 五氯化磷 、 三氯氧磷 作用下， 以97%的产率得到1,3-dichloro-6,7-dimethylisoquinoline
  参考文献：
  名称：

  二和三烷基-3-哌嗪子异喹啉和相关化合物的合成作为潜在的抗抑郁药

  摘要：

  经由二烷基和四烷基化的1-茚满酮作为中间体合成了一系列二烷基和四烷基-3-哌嗪子异喹啉和相关化合物。

  DOI：

  10.1002/jhet.5570240326
• 作为产物：
  描述：

  3,4-二甲基苯甲醛 在 palladium on activated charcoal 盐酸 、 亚硝酸乙酯 、 磷酸 、 氢气 、 phosphorus pentoxide 作用下， 以 吡啶 、 乙醚 、 乙醇 为溶剂， 120.0 ℃ 、10.0 MPa 条件下， 反应 29.5h， 生成 5,6-dimethyl-2-oximino-1-indanone
  参考文献：
  名称：

  二和三烷基-3-哌嗪子异喹啉和相关化合物的合成作为潜在的抗抑郁药

  摘要：

  经由二烷基和四烷基化的1-茚满酮作为中间体合成了一系列二烷基和四烷基-3-哌嗪子异喹啉和相关化合物。

  DOI：

  10.1002/jhet.5570240326

文献信息

• [EN] DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS<br/>[FR] COMPOSÉS DÉRIVÉS DE DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE
  申请人：UCB BIOPHARMA SRL

  公开号：WO2021130259A1

  公开（公告）日：2021-07-01

  The present invention relates to dihydrocyclopenta-isoquinoline-sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FcεRI receptor.

  本发明涉及式(I)的二氢环戊基异喹啉磺胺衍生物，以及制备它们的方法、含有它们的药物组合物以及它们在治疗由IgE引起的疾病（如过敏反应、非过敏性肥大细胞反应或某些自身免疫反应）中的用途，特别是由IgE与FcεRI受体相互作用引起的疾病。
• The Identification of Indacaterol as an Ultralong-Acting Inhaled β₂-Adrenoceptor Agonist
  作者：François Baur、David Beattie、David Beer、David Bentley、Michelle Bradley、Ian Bruce、Steven J. Charlton、Bernard Cuenoud、Roland Ernst、Robin A. Fairhurst、Bernard Faller、David Farr、Thomas Keller、John R. Fozard、Joe Fullerton、Sheila Garman、Julia Hatto、Claire Hayden、Handan He、Colin Howes、Diana Janus、Zhengjin Jiang、Christine Lewis、Frederique Loeuillet-Ritzler、Heinz Moser、John Reilly、Alan Steward、David Sykes、Lauren Tedaldi、Alexandre Trifilieff、Morris Tweed、Simon Watson、Elke Wissler、Daniel Wyss

  DOI：10.1021/jm100068m

  日期：2010.5.13

  Following a lipophilicity-based hypothesis, an 8-hydroxyquinolinone 2-aminoindan derived series of beta(2)-adrenoceptor agonists have been prepared and evaluated for their potential as inhaled ultralong-acting bronchodilators. Determination of their activities at the human beta(2)-adrenoceptor receptor showed symmetrical substitution of the 2-aminoindan moiety at the 5- and 6-positions delivered the targeted intermediate potency and intrinsic-efficacy profiles relative to a series of clinical reference beta(2)-adrenoceptor agonists. Further assessment with an in vitro superfused electrically stimulated guinea-pig tracheal-strip assay established the onset and duration of action time courses, which could be rationalized by considering the lipophilicity, potency, and intrinsic efficacy of the compounds. From these studies the 5,6-diethylindan analogue indacaterol 1c was shown to possess a unique profile of combining a rapid onset of action with a long duration of action. Further in vivo profiling of 1c supported the long duration of action and a wide therapeutic index following administration to the lung, which led to the compound being selected as a development candidate.